(thirdQuint)Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS).

 New users of the LNG IUS will be eligible.

 Subjects will be randomized to receive tamoxifen 10 mg BID for 7 days or placebo.

 Study drug will be started 3 weeks after placement of the IUS.

 Subjects will maintain a record of daily bleeding and spotting using an electronic text messaging diary.

.

 Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)@highlight

This study evaluates the ability of tamoxifen to improve frequent or prolonged bleeding in new users of the 52mg levonorgestrel-releasing intrauterine device.

 Half of participants will receive a course of tamoxifen three weeks after insertion of the IUD, while the other half of participants will receive a course of placebo.

